- $34.93m
- $9.99m
- $4.01m
Brief: Cervomed Announces Key Takeaways From Oral Presentations At The 17Th Clinical Trials On Alzheimer's Disease Conference
Live Markets: Brainy efforts underway, but still some way to go for neuro drug developers
Brief: Cervomed Inc Files For Mixed Shelf Offering Of $250 Million-SEC Filing
Brief: Cervomed Inc Notified Btig, Llc That Co Is Terminating Sales Agreement, Effective October 11
CervoMed Inc reports results for the quarter ended in January - Earnings Summary
CervoMed Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Cervomed Announces Completion Of Enrollment In Phase 2B Rewind-Lb Clinical Trial Of Neflamapimod For The Treatment Of Patients With Dementia With Lewy Bodies
U.S. RESEARCH ROUNDUP-Autodesk, McKesson, Microstrategy
Brief: Cervomed To Appoint William Elder As Chief Financial Officer
CervoMed Inc reports results for the quarter ended in March - Earnings Summary
Brief: CervoMed Files Prospectus Related To Resale By Selling Stockholders Of Up To 5.1 Mln Shares
CervoMed Inc expected to post a loss of 39 cents a share - Earnings Preview
CervoMed Inc reports results for the quarter ended in December - Earnings Summary
CervoMed Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: CervoMed Announces Up To $149.4 Mln Private Placement Financing
CervoMed Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: CervoMed Announces Presentation Of Biomarker Data From AscenD-LB Phase 2a Trial, Preclinical Data
Brief: Cervomed Publishes Positive Results From Ascend-Lb Phase 2A Trial
Brief: CervoMed Inc - Phase 2B Rewind-Lb Study Underway